Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
$4.28
-9.1%
$6.18
$4.24
▼
$25.95
$239.90M1.19716,104 shs632,002 shs
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
$6.39
+0.3%
$6.01
$3.63
▼
$8.98
$243.17M0.99377,549 shs218,736 shs
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
$8.10
-6.3%
$11.32
$2.60
▼
$16.45
$261.40MN/A101,465 shs82,672 shs
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
$15.51
-5.2%
$26.44
$15.47
▼
$44.00
$62.22M0.2822,303 shs10,589 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
-9.13%-22.88%-22.32%-54.85%-48.06%
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
+0.24%-0.47%+0.31%+40.75%-14.69%
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
-6.25%-13.37%-20.20%-14.38%+186.22%
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
-5.20%-21.23%-44.15%-53.37%-51.89%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
$4.28
-9.1%
$6.18
$4.24
▼
$25.95
$239.90M1.19716,104 shs632,002 shs
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
$6.39
+0.3%
$6.01
$3.63
▼
$8.98
$243.17M0.99377,549 shs218,736 shs
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
$8.10
-6.3%
$11.32
$2.60
▼
$16.45
$261.40MN/A101,465 shs82,672 shs
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
$15.51
-5.2%
$26.44
$15.47
▼
$44.00
$62.22M0.2822,303 shs10,589 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
-9.13%-22.88%-22.32%-54.85%-48.06%
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
+0.24%-0.47%+0.31%+40.75%-14.69%
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
-6.25%-13.37%-20.20%-14.38%+186.22%
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
-5.20%-21.23%-44.15%-53.37%-51.89%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
2.63
Moderate Buy$29.00577.57% Upside
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
1.60
Reduce$6.501.72% Upside
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
2.67
Moderate Buy$9.0011.11% Upside
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
2.78
Moderate Buy$55.83259.98% Upside

Current Analyst Ratings Breakdown

Latest VTVT, TTRX, LFCR, and BIOA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/18/2026
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
Lower Price TargetBuy$21.00 ➝ $20.00
11/16/2026
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
Reiterated RatingSell (E+)
11/9/2026
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
Reiterated RatingBuy
11/6/2026
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
DowngradeHold ➝ Strong Sell
11/4/2026
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
Reiterated RatingSell (D-)
10/26/2026
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
UpgradeSell (E+) ➝ Sell (D-)
10/23/2026
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
UpgradeSell ➝ Hold$10.00
10/16/2026
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
UpgradeSell (E+) ➝ Sell (D-)
10/14/2026
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
Reiterated RatingBuy$57.00
10/11/2026
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
Initiated CoverageNeutral$8.00
10/11/2026
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
UpgradeHold
(Data available from 11/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
$8.99M21.88N/AN/A$7.54 per share0.57
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
$128.87M1.88N/AN/A($1.94) per share-3.29
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
N/AN/AN/AN/A$0.19 per shareN/A
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
$1.02M60.98N/AN/A$17.37 per share0.89
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
-$80.61M-$2.55N/AN/AN/A-1,253.60%-31.42%-29.59%N/A
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
N/A-$1.86N/AN/AN/A-56.80%N/A-29.53%N/A
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
-$3.19M-$0.43N/AN/AN/AN/A-261.87%-70.18%N/A
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
-$26.97M-$0.92N/AN/AN/AN/A-10.15%-8.65%N/A

Latest VTVT, TTRX, LFCR, and BIOA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/9/2026Q3 2026
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
N/A-$0.21N/A-$0.21N/AN/A
11/5/2026Q3 2026
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
-$0.68-$0.73-$0.05-$0.73N/A$0.30 million
11/5/2026Q3 2026
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
-$1.09-$0.94+$0.15-$0.94$0.33 millionN/A
11/4/2026Q1 2027
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
-$0.2975-$1.08-$0.7825-$1.08$25.57 million$25.32 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
N/AN/AN/AN/AN/A
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
N/AN/AN/AN/AN/A
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
N/AN/AN/AN/AN/A
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
N/A
15.51
15.51
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
N/A
3.84
2.59
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
1.01
3.19
3.19
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
N/A
11.19
11.19

Institutional Ownership

CompanyInstitutional Ownership
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
N/A
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
83.36%
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
N/A
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
17.51%

Insider Ownership

CompanyInsider Ownership
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
17.55%
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
32.68%
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
55.89%
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
5.99%
CompanyEmployeesShares OutstandingFree FloatOptionable
BioAge Labs, Inc. stock logo
BIOA
BioAge Labs
6245.96 million37.89 millionOptionable
Lifecore Biomedical, Inc. stock logo
LFCR
Lifecore Biomedical
38237.91 million25.52 millionOptionable
Turn Therapeutics Inc. stock logo
TTRX
Turn Therapeutics
230.57 million13.49 millionOptionable
vTv Therapeutics Inc. stock logo
VTVT
vTv Therapeutics
264.01 million3.77 millionNot Optionable

Recent News About These Companies

vTv Therapeutics stock jumps on FDA orphan drug status

New MarketBeat Followers Over Time

Media Sentiment Over Time

BioAge Labs stock logo

BioAge Labs NASDAQ:BIOA

$4.28 -0.43 (-9.13%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$4.30 +0.01 (+0.35%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging. Our primary focus is metabolic disease, one of the greatest global healthcare challenges. Azelaprag, our lead product candidate, is an orally available small molecule that has been well-tolerated in 265 individuals across eight Phase 1 clinical trials. In preclinical obesity models, azelaprag demonstrated the ability to more than double the weight loss induced by a glucagon-like-peptide-1 receptor (GLP-1R) agonist while also restoring healthy body composition and improving muscle function. These preclinical results are supported by our Phase 1b clinical trial in older adults on bed rest where we observed decreased muscle atrophy, preservation of muscle quality and improved metabolism in subjects treated with azelaprag over a 10-day period. We plan to assess azelaprag’s potential to drive significant improvements in weight loss when combined with a GLP-1R agonist in two Phase 2 clinical trials. While the results of these preclinical studies and early clinical trials have demonstrated the potential use of azelaprag for the treatment of metabolic disease, they may not be predictive of the results of later-stage clinical trials. The ongoing STRIDES clinical trial will assess azelaprag in combination with tirzepatide, marketed as Zepbound® by Eli Lilly and Company (Lilly), with topline results anticipated in the third quarter of 2025. The second Phase 2 clinical trial will assess azelaprag in combination with semaglutide, marketed as Wegovy® by Novo Nordisk, with initiation expected in the first half of 2025 and topline results expected in the second half of 2026. We believe these trials will directly support our ultimate therapeutic goal of developing an all-oral combination product for obesity. We also intend to initiate an insulin sensitivity proof-of-concept trial of azelaprag monotherapy in the first half of 2025 to support potential indication expansion. We expect to report topline results from this proof-of-concept trial in the second half of 2025. We are also developing orally available small molecule brain-penetrant NLRP3 inhibitors for the treatment of diseases driven by neuroinflammation. We anticipate submitting an Investigational New Drug application (IND) for an NLRP3 inhibitor in the second half of 2025 and, if cleared, initiating a Phase 1 clinical trial in the first half of 2026. Our approach: Targeting human aging biology to treat chronic metabolic diseases The burden of many serious and chronic diseases—including cardiovascular disease and diabetes—increases with age. However, there is substantial natural variation in the human population, resulting in a broad range of aging trajectories and outcomes, with some people experiencing much longer lifespans as well as delayed disease onset. We created our company to identify biological pathways associated with longer, healthier human lifespans and to develop pharmaceutical products that can modulate these pathways with the intent to prevent and reverse specific diseases, focusing on metabolic diseases. --- Our approach starts with human data. We examine the impact of the molecular changes that happen naturally as people age and study how these changes drive both functional decline (e.g., loss of muscle strength) and disease risk (e.g., obesity, insulin resistance, dyslipidemia, hypertension). To develop new insights into the biological drivers of aging, we have generated proprietary longitudinal human datasets based on exclusive access to a unique resource: serial biobanked human samples coupled with health records and functional measurements collected for up to 50 years, capturing individual aging trajectories measured over several decades. We analyze these samples using state-of-the-artmolecular profiling technologies, measuring thousands of biologically relevant molecules, and then apply computational tools to the resulting data to extract potential drivers of a long and healthy lifespan. --- We have selected chronic metabolic diseases as our primary focus within age related chronic diseases, given their high prevalence and resulting potential for impact on population health. Chronic metabolic diseases represent some of the largest addressable therapeutics markets. Through our approach, we expect to target outsized commercial opportunities, initially within the obesity and diabetes landscape. For instance, according to third-party estimates, the global market for GLP-1R agonists, including those used to treat diabetes, is expected to grow to $150 billion by 2031. We were incorporated under the laws of the State of Delaware on April 1, 2015, under the name BioAge Labs, Inc. Our principal executive offices are located at 1445A South 50th Street, Richmond, California.

Lifecore Biomedical stock logo

Lifecore Biomedical NASDAQ:LFCR

$6.39 +0.02 (+0.31%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$6.38 0.00 (-0.08%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Lifecore Biomedical, Inc., together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures. It also provides services, such as technology development, material component changes, analytical method development, formulation development, pilot studies, stability studies, process validation, and production of materials for clinical studies to its partners for HA-based and non-HA based aseptically formulated and filled products. The company was formerly known as Landec Corporation and changed its name to Lifecore Biomedical, Inc. in November 2022. Lifecore Biomedical, Inc. was founded in 1965 and is headquartered in Chaska, Minnesota.

Turn Therapeutics stock logo

Turn Therapeutics NASDAQ:TTRX

$8.10 -0.54 (-6.25%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$8.07 -0.03 (-0.31%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events. Our proprietary platform has been validated across multiple FDA-cleared medical devices. Our primary development programs focus on dermatological diseases, including moderate to severe eczema and onychomycosis. Our company’s origin is rooted in the personal journey of our founder, who developed a topical ointment to heal his own chronic, treatment-resistant wounds using the PermaFusion platform he developed. His initial formulation, now known as Hexagen (“Hexagen”) suspends certain antimicrobial/anti-inflammatory compounds in petrolatum without known cytotoxicity, irritation or sensitization. This formula has received three FDA clearances and has been utilized extensively in humans, which we believe demonstrates both technical proof of concept and meaningful therapeutic effects. The formula also has been demonstrated to provide anti-inflammatory immunological signaling (IL 36, IL 31, IL 4 inhibition), in-vivo nail penetration with fungal pathogen elimination, and other potential therapeutic benefits. These products are not presently on the market, and we are not currently generating revenue from these devices, as we focus on drug development of our core technology. In addition to our dermatology and wound programs, we are exploring broader applications of our PermaFusion technology. In partnership with a leading global nonprofit organization, we are attempting to develop intranasal vaccines with sufficient thermostability to withstand distribution without deep-freeze. Our goal is to eliminate the need for frozen storage and, thus, enable deployment and delivery to low-resource settings that do not maintain suitable cold storage infrastructure required for administration of modern-day vaccines. Furthermore, if we are successful in this initial program, we believe there may be opportunities to develop additional vaccines in thermostable, intranasal form. By reducing cold-storage infrastructure requirements and therefore enabling standard shipping of such vaccines, we believe intranasal vaccines have the potential to enhance patient uptake by enabling immunization in a broader variety of settings including in clinic, hospital and home-health settings. We believe this initiative highlights our platform’s versatility and its potential to unlock new therapeutic categories beyond dermatology. We have also completed preclinical, in-vivo xenograft studies for herpes zoster ophthalmicus (shingles of the eye) and basal cell carcinoma. A mildly reformulated version of the Hexagen formula was employed for the ocular study and compared this reformulation with placebo as a topical ocular agent intended to reduce viral load of herpes zoster in an animal model. Results obtained showed an 85% reduction in viral load compared to placebo without adverse events. For the basal cell carcinoma xenograft study, the Hexagen formula was compared to both placebo and 5-Fluorouracil (standard of care topical chemotherapy) as a topical treatment intended to reduce basal cell tumor size. The Hexagen formula showed an approximate 29% comparative reduction in tumor size to the placebo and an approximate 20% comparative reduction in tumor size compared to 5-Fluorouracil. We believe these preclinical in-vivo studies suggest meaningful potential in these indications, which we may continue to explore at the conclusion of our lead drug programs. We believe such exploratory results further underscore the potential breadth of opportunity enabled by our platform. We were initially formed on January 6, 2015, as Global Health Solutions, LLC, a Delaware limited liability company. On October 12, 2018, Global Health Solutions, LLC converted to a Delaware corporation under the name Global Health Solutions, Inc., dba Turn Therapeutics. Immediately prior to the effectiveness of the registration statement of which this prospectus forms a part, we intend to change our name to Turn Therapeutics Inc. Our principal executive offices are located in Westlake Village, CA.

vTv Therapeutics stock logo

vTv Therapeutics NASDAQ:VTVT

$15.51 -0.85 (-5.20%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$15.74 +0.23 (+1.52%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

vTv Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes. It is also developing HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 inhibitor, which is in Phase III trial for the treatment of psoriasis, COPD, and atopic dermatitis, as well as TTP-RA, a RAGE antagonist for type 1 diabetes prevention. In addition, the company's other programs include HPP3033, a non-electrophilic therapeutic approach to activating the nuclear factor erythroid 2related factor 2 (Nrf2) pathway for the treatment of chronic diseases associated with oxidative stress; and Azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for glioblastoma, other cancers, and cancer treatment-related conditions. vTv Therapeutics Inc. has license agreements with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593 for therapeutic, prophylactic, and diagnostic application; and Anteris Bio, Inc. to develop and commercialize HPP971, a Nrf2 activator, as well as with Cantex Pharmaceuticals, Inc.; Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.